The funding round combines backing from the Development Bank of Wales and Women Angels of Wales with grant support.
"We’re working hard to encourage more women to get involved with angel investing. Our support for Kaydiar is a great example of bringing together grant, angel and institutional funding to provide the resources to support the development of an innovative, early-stage company in Wales. Our syndicate is delighted to support Heather Smart and David Barton, two young podiatrists who are applying new technologies to improve patient outcomes in the footcare sector. We all look forward to working with Kaydiar to build a world class company."
Parkwalk Advisors led the round with a £1.5m investment alongside a £700k grant from Innovate UK.
"AI as a technology block has huge potential in the sleep tech industry and equally the specific ScentTech sector within that, in which OW is a leader. ML and AI are opening up capabilities of predictions and data integration merging patterns from individual real-time biofeedback with many other core variables around sleep, user profile and environment. OW’s AI engine has been in development for over 5 years. Able to model multiple scent designs through the sleep cycle but taking into account all the huge factors noted above using predictive modelling and database analysis to deliver highly optimised and individual point solutions."
Parkwalk Advisors led the raise alongside a grant from Innovate UK to support the development of sleep technology applications.
"Smell can be our most powerful sense and only now are we realising the potential of technology to translate it for experience, welfare and health. This technology has enormous commercial applications which this new investment will help us unlock."
The Scottish laser technology specialist has raised over £1m from existing investors and Innovate UK to fund healthcare product rollouts and emissions monitoring tools.
"Designing and manufacturing state-of-the-art ultrafast infra-red lasers brings huge value and efficiencies to the global healthcare market. Our new '920' builds on a decade of research and IP development to extend our product roadmap."
